Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 57

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 57
---
 the repayments in (ii) above will be adjusted accordingly. All other terms of the Loan Agreement remain
the same.

32

November 2024 Registered Direct Offering

On November 21, 2024, we sold to certain funds associated with
Highbridge Capital Management LLC, or Highbridge, in a registered direct offering, 103,038 ADSs and pre-funded warrants to purchase 308,749
ADSs. Each ADS and pre-funded warrant were sold together with ordinary warrants to purchase up to an aggregate of 205,894 ADSs. The purchase
price was $21.856 per ADS and accompanying ordinary warrant and $21.852 per pre-funded warrant and accompanying ordinary warrant. The
pre-funded warrants are immediately exercisable at an exercise price of $0.004 per ADS, subject to adjustment as set forth therein, and
will not expire until exercised in full. The ordinary warrants have an exercise price of $23.60 per ADS, subject to adjustment as set
forth therein, are immediately exercisable, and have a 4-year term from the issuance date. Aggregate gross proceeds from the offering
(without taking into account any proceeds from any future exercises of pre-funded warrants or ordinary warrants) were $9.0 million.

April 2024 Registered Direct Offering

On April 1, 2024, we sold to certain investors, in a registered
direct offering, 187,500 of our ADSs and warrants to purchase up to an aggregate of 187,500 ADSs at a combined purchase price of $32.00
per ADS and accompanying warrant. The warrants have a 5-year term from the issuance date. The exercise price of each warrant is $32.00
per ADS, subject to adjustment as set forth therein. Aggregate gross proceeds from the offering (without taking into account any proceeds
from any future exercises of warrants) were $6.0 million.

Out Licensing of Motixafortide in Asia

On August 27, 2023, we entered into a License Agreement, or the Gloria License Agreement,
with Hong Seng Technology Limited, or HST, and Gloria, and/or with HST, the Gloria Licensee, pursuant to which we granted HST an exclusive,
royalty-bearing, sublicensable license with respect to the intellectual property rights and know-how associated with motixafortide in
order to develop and commercialize motixafortide in Asia (other than Israel and certain other countries), or the Gloria Territory, and
to